Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
Cytokinetics, a specialty cardiovascular biopharmaceutical company, announced the pricing of an upsized underwritten public offering of approximately 9.86 million shares of common stock at $71 per share, expected to raise gross proceeds of around $700 million. The offering is underwritten by major investment banks and is slated to close by May 8, 2…